Citi analyst Yigal Nochomovitz opened a "positive 30-day Catalyst Watch" on shares of Apellis Pharmaceuticals with the FDA action date for pegcetacoplan in geographic atrophy on February 26. The analyst expects FDA approval and believes the stock will react "very favorably to this highly material de-risking event." The firm also thinks the "M&A thesis will gain traction" with approval and has previously called out Bayer, Novartis, and Roche as potentially interested parties. Citi keeps a Buy rating on Apellis with an $86 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- JPMorgan sees Apellis rally with FDA action date fast approaching
- Apellis expects 2022 Empaveli revenue of $65M
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sell these stocks now, proven algorithm says
- Citi would buy Apellis on dip after talking to management about CMO change